Collaboration agreement additional pre-clinical development milestone payment eligible to receive.

No definition available.

Name:	rxdx_CollaborationAgreementAdditionalPreClinicalDevelopmentMilestonePaymentEligibleToReceive
Namespace Prefix:	rxdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration agreement pre-clinical development milestone payment received upon clinical candidate selected.

+ References

No definition available.

+ Details

Name:	rxdx_CollaborationAgreementPreClinicalDevelopmentMilestonePaymentReceivedUponClinicalCandidateSelected
Namespace Prefix:	rxdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration agreement pre-clinical development milestone payment received upon finalization of development plan.

+ References

No definition available.

+ Details

Name:	rxdx_CollaborationAgreementPreClinicalDevelopmentMilestonePaymentReceivedUponFinalizationOfDevelopmentPlan
Namespace Prefix:	rxdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration agreement upfront payment received upon agreement execution.

+ References

No definition available.

+ Details

Name:	rxdx_CollaborationAgreementUpfrontPaymentReceivedUponAgreementExecution
Namespace Prefix:	rxdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Funding percentage for third-party development costs set forth in development plan.

+ References

No definition available.

+ Details

Name:	rxdx_FundingPercentageForThirdPartyDevelopmentCostsSetForthInDevelopmentPlan
Namespace Prefix:	rxdx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

License agreement expiration term.

+ References

No definition available.

+ Details

Name:	rxdx_LicenseAgreementExpirationTerm
Namespace Prefix:	rxdx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=rxdx_CedarsSinaiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rxdx_CedarsSinaiMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=rxdx_VestedCommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=rxdx_UnvestedRestrictedCommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rxdx_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rxdx_CoDevelopmentAndManufacturingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rxdx_DrFalkPharmaGMBHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rxdx_CompanionDiagnosticsDevelopmentAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rxdx_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jul. 31, 2020	Sep. 30, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued			38,960,716	1,768,325
Revenue recognized			$ 3,129,000	$ 1,229,000
Deferred revenue			19,872,000	6,473,000	$ 1,542,000
Cedars-Sinai Agreement \| Cedars-Sinai
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expiration term		3 years
Cedars-Sinai Agreement \| Cedars-Sinai \| Vested Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued		257,500
Cedars-Sinai Agreement \| Cedars-Sinai \| Unvested Restricted Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued		335,000
License Agreement \| Cedars-Sinai
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expiration term		10 years
Falk Agreement \| Falk
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding percentage third-party development costs set forth in development plan	25.00%
Collaboration agreement, upfront payment received upon agreement execution	$ 2,500
Collaboration agreement, pre-clinical development milestone payment received upon finalization of development plan			2,500
Collaboration agreement, pre-clinical development milestone payment received upon clinical candidate selected	10,000
Collaboration agreement additional pre-clinical development milestone payment eligible to receive	$ 5,000
Revenue recognized			2,750,000	437,000
Deferred revenue			18,691,000	4,763,000
Takeda Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized			379,000	792,000
Deferred revenue			1,181,000	1,710,000	$ 1,542,000
Takeda Collaboration Agreement \| Takeda Pharmaceutical Company Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized			400,000	800,000
Deferred revenue			$ 1,200,000	$ 1,700,000